---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-072891"
form_type: "8-K"
ticker: null
cik: "0001567892"
company_name: "Keenova Therapeutics plc"
filed_at: "2025-08-01T23:59:59+00:00"
generated_at: "2026-05-17T21:50:03.448318+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Mallinckrodt completes acquisition of Endo; new $1.35B credit facilities

## Summary
- Acquisition closed July 31, 2025; Endo shareholders received $1.31 cash + 0.2575 Mallinckrodt shares per share.
- New $1.35B senior secured facilities: $1.2B term loan (fully drawn Aug 1) and $150M revolver; maturity July 31, 2030.
- Existing debt refinanced: ~$385.5M term loans and ~$477.2M notes repaid; make-whole premiums of ~$10.6M and ~$13.7M paid.
- Board reconstituted: three directors resigned; four Endo directors (Efron, Hirsch, Langlois, Yoskowitz) and Leslie Donato appointed.
- Post-merger committees set: Efron Chair; Langlois chairs Audit; Bisaro, Dorton, Zinman on committees.

## SEC filing metadata
- accession: 0001104659-25-072891
- form_type: 8-K
- cik: 0001567892
- company_name: Keenova Therapeutics plc
- filed_at: 2025-08-01T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 1.02, 2.01, 2.02, 7.01, 2.03, 2.04, 3.03, 5.02, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1567892/000110465925072891/0001104659-25-072891-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1567892/000110465925072891/tm2522037d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-072891
- JSON: https://secwatch.observer/filing/0001104659-25-072891.json
- Plain text: https://secwatch.observer/filing/0001104659-25-072891.txt

## Key facts
- Debt Financings
  Keenova Therapeutics plc incurred credit facility of $1,350,000,000 in aggregate principal amount of senior secured credit facilities, comprising (i) a $1,200,000,000 senior with Wilmington Savings Fund Society, FSB as administrative agent and collateral agent, and OPY Credit Corp., as trading agent, and the lenders named therein at base rate (subject to a 2.00% floor) plus 600 basis points, or Term SOFR (subjec maturing July 31, 2030.
  - Instrument: credit facility
  - Principal: $1,350,000,000 in aggregate principal amount of senior secured credit facilities, comprising (i) a $1,200,000,000 senior
  - Counterparty: Wilmington Savings Fund Society, FSB as administrative agent and collateral agent, and OPY Credit Corp., as trading agent, and the lenders named therein
  - Rate: base rate (subject to a 2.00% floor) plus 600 basis points, or Term SOFR (subjec
  - Maturity: July 31, 2030
  - Event: incurrence
  source text: On July 31, 2025, in connection with the consummation of the Transactions, ST 2020, Inc. (“ Parent ”), a wholly owned subsidiary of Mallinckrodt, and MEH, Inc. (the “ Borrower ”), a wholly owned subsidiary of Parent, entered into a credit agreement (the “ New Credit Agreement ”) with the lenders named therein, Wilmington Savings Fund Society, FSB, as administrative agent and collateral agent, and OPY Credit Corp., as trading agent, providing for $1,350,000,000 in aggregate principal amount of senior secured credit facilities (the “ Facilities ”), comprising (i) a $1,200,000,000 senior secured term loan facility (the “ Term Facility ”) and (ii) a $150,000,000 senior secured revolving credit facility (the “ Revolving Facility ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1567892/000110465925072891/0001104659-25-072891-index.htm
- M&A Transactions
  Keenova Therapeutics plc completed an acquisition involving Endo, Inc. for approximately $1.31 in cash and 0.2575 of a Mallinckrodt ordinary share (closed 2025-07-31).
  - Action: acquisition
  - Counterparty: Endo, Inc.
  - Consideration: approximately $1.31 in cash and 0.2575 of a Mallinckrodt ordinary share
  - Closing: 2025-07-31
  source text: On July 31, 2025, pursuant to the terms of the Transaction Agreement, at the effective time of the Merger (the “ Merger Effective Time ”), each share of common stock, par value $0.001 per share, of Endo (the “ Endo common stock ”) issued and outstanding as of immediately prior to the Merger Effective Time, other than the shares of Endo common stock owned by Endo, any Endo subsidiary, Mallinckrodt, Merger Sub or any of their respective subsidiaries, was cancelled and converted into the right to receive approximately $1.31 in cash (the “ Per Share Cash Consideration ”) and 0.2575 of a Mallinckrodt ordinary share (the “ Per Share Stock Consideration, ”), without interest and subject to applicable withholding.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1567892/000110465925072891/0001104659-25-072891-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.